Chinese drug discovery firm BioMap bags $100m Series A led by GGV Capital

Chinese drug discovery firm BioMap bags $100m Series A led by GGV Capital

BioMap, a Chinese AI-driven R&D platform that focuses on precision medicine, has raised $100 million in a Series A round led by global investment firm GGV Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter